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Symptoms Score (IPSS). 44 articles which used the IPSS were able to detect a signiﬁcant 
change in the symptom scores. The remaining articles used various other PRO mea-
sures for their BPH endpoints. Of the 70 articles yielded from the Phase II search, 11 
were utility studies, 25 were BPH-speciﬁc articles, 29 were overactive bladder (OAB)-
speciﬁc articles, and 5 were urge urinary incontinence (UUI)-speciﬁc articles. From the 
BPH, OAB, and UUI articles, we identiﬁed the key QOL instruments utilized to 
measure the various domains key to BPH. CONCLUSIONS: There have been a large 
number of PRO measures used in the literature to study BPH and related endpoints. 
It is clear that the IPSS has been used in the majority of the studies focused on BPH 
symptoms (81.25% of the ones reviewed).
PR2
IMPROVEMENT IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY 
FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED 
WITH ADALIMUMAB PLUS METHOTREXATE: WORK OUTCOMES AND 
THEIR CORRELATIONS WITH CLINICAL AND RADIOGRAPHIC 
MEASURES FROM A RANDOMIZED CONTROLLED TRIAL COMPANION 
STUDY
van Vollenhoven R1, Cifaldi M2, Ray S2, Chen N2, Weisman MH3
1Karolinska Institutet, Stockholm, Sweden, 2Abbott Laboratories, Abbott Park, IL, USA, 
3Cedars Sinai Medical Center, Los Angeles, CA, USA
OBJECTIVES: To evaluate work productivity of paid workers and homemakers with 
rheumatoid arthritis (RA) treated with adalimumab plus methotrexate (ADAMTX), 
ADA monotherapy, or MTX monotherapy, and to determine baseline predictors of 
work outcomes. METHODS: Data were from the DE032 companion study to 
PREMIER, a 2-year, randomized controlled trial of MTX-naïve patients with early 
RA (3 years). Absenteeism (number of missed work days), presenteeism (patients’ 
self-judgment of effects of RA on work performance), and employment status data 
were collected from self-reports at baseline and varying timepoints during the 2-year 
study. For analyses of cumulative variables, adjustments were made for duration of 
patients’ participation in DE032. RESULTS: Of 799 patients in PREMIER, 664 par-
ticipated in DE032 (ADAMTX, n  219; ADA monotherapy, n  231; MTX mono-
therapy, n  214). Percentages of paid workers and homemakers were similar across 
treatment groups. Among paid workers, the number of missed work days at Year 2 
was signiﬁcantly fewer for ADAMTX (17.4 days) and ADA monotherapy (18.7 days) 
vs. MTX monotherapy (36.9 days, p  0.0001). Improvement in presenteeism was 
greater with ADAMTX vs. MTX monotherapy (p  0.05 at most visits). The percent-
age of patients who retained or gained employment over the 2-year study was 57.6% 
(121 of 210) for ADAMTX, 51.8% (116 of 224) for ADA monotherapy, and 47.6% 
(100 of 210) for MTX monotherapy. The odds of retaining/gaining employment were 
signiﬁcantly greater for ADAMTX vs. MTX monotherapy (odds ratio [OR]  1.53, 
95% conﬁdence interval [CI]: 1.04–2.26, p  0.032). Retaining/gaining employment 
was signiﬁcantly associated with younger age, female sex, and better baseline scores 
on the Health Assessment Questionnaire, Short Form 36 Health Survey, and radio-
graphic progression (joint space narrowing, joint erosion, total Sharp score). 
 CONCLUSIONS: ADAMTX was associated with more positive work outcomes vs. 
MTX monotherapy. Productivity outcomes were similar for paid workers and home-
makers. Radiographic progression at baseline was predictive of employment status.
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EFFECT OF PREHOSPITALIZATION PERIOD AND TYPE OF PESTICIDES 
ON OUTCOMES IN ACUTE ORGANOPHOSPHORUS POISONING
Rose Xavier V1, Thunga G2, Sam KGS2, Kehra K3
1Manipal University, Udupi, karnataka, India, 2Manipal University, Udupi, Karnataka, India, 
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OBJECTIVES: To study the effect of prehospitalization period and type of pesticides 
on outcomes in acute organophosphorus poisoning METHODS: A prospective study 
was conducted with organophosphate poisoning patients admitted to our emergency 
department between January 2007 and January 2008. Information regarding the age, 
sex, occupation, prehospitalization period, type of agent, route of poisoning, clinical, 
laboratory ﬁndings, type of management and subsequent outcome were recorded from 
the patient medical records. The outcomes were analyzed in terms of percentage of 
intermediate syndrome, requirement of ventilation, duration of hospitalization period, 
percentage of mortality, percentage of sequel and percentage of recovery. The out-
comes were compared with preospitalization period and type of pesticides. RESULTS: 
During the study period, 100 patients were admitted to the emergency ward with acute 
organophosphorus poisoning. The estimated mean prehospitalization period after the 
exposure was 2.5 o 2.1 hours. There were 68 male and 32 female patients. The most 
affected age group was 21–30 years (60%). Oral ingestion (99%) was found to be 
the most common route of poisoning. The most frequent reason for poisoning was 
attempted suicide (98%). The most common organophosphate compounds exposed 
were type Ia which was extremely hazardous (60%) and type II which was moderately 
hazardous (25%).Comparing the outcomes with the mean prehosptalization period 
showed that it did not signiﬁcantly affect outcomes in acute OP poisoning, but the 
incidence of intermediate syndrome was higher in these patients. There was signiﬁcant 
correlation between type of compound and outcome. The incidence of intimidate 
syndrome, requirement for ventilation and rate of mortality was signiﬁcantly higher 
in type Ia compounds when compared to other type of pesticides. CONCLUSIONS: 
The prehospitalization period had no inﬂuence on outcomes in acute OP poisoning, 
where as type of OP compounds signiﬁcantly effect incidence of intimidate syndrome, 
requirement for ventilation and rate of mortality.
PR4
QUALITY OF LIFE IN PATIENTS WITH EPIDERMOLYSIS BULLOSA
Tabolli S, Uras C, Paradisi A, Sampogna F, Di Pietro C, Abeni D, Zambruno G
IDI IRCCS, Rome, Italy
Epidermolysis bullosa (EB) is a rare, inherited group of disorders characterized by 
blistering of the skin following friction or mechanical trauma. EB has a clinical and 
socio-economic impact on patients and their families. OBJECTIVES: To assess the 
Quality of Life (QoL) in patients with EB and to determine disease burden. METHODS: 
The study was an observational, cross-sectional postal survey. 185 patients were 
invited to participate. Different sets of questionnaires (SF-36, Skindex-29, GHQ-12, 
EQ-5D) were sent to patients according to age. The perceived severity of the disease 
was evaluated by patients or by the mothers of the younger EB children, using the 
Patient Global Assessment 5-point scale. Caregivers received the Family Strain Ques-
tionnaire (FSQ). RESULTS: A total of 125 respondents were analysed. EB patients 
showed lower values in physical components of SF-36, while the mental ones were 
not signiﬁcantly impaired. Among EB types, junctional EB and severe generalized 
recessive dystrophic EB patients reported lower values and their General Health scale 
was signiﬁcantly different from EB simplex. There were no signiﬁcant differences 
among EB types/subtypes for Skindex-29 values. Females had a worse QoL compared 
to males in each Skindex-29 and SF-36 scales (p  0.05). GHQpositive cases were 
48% among females, 16% among males (p  0.003); GHQpositive cases had a worse 
QoL compared to GHQnegative. The patient QoL and the family burden increased 
with increasing patient’s perceived disease severity and with increasing patient’s body 
surface involved. No differences were seen among EB types for the family burden. 
CONCLUSIONS: In EB patients mental components of SF-36 scores are similar to 
the normal population. The perceived disease severity and skin area involved are rel-
evant for QoL independently by EB type/subtype. EB imposes a heavy burden on the 
caregiver and the family. Psychological support and close monitoring of QoL may 
help EB patients and their caregivers.
PODIUM SESSION I: RESEARCH ON METHODS: I
MC1
VALORACIÓN SOCIAL DE LOS ESTADOS DE SALUD EQ-5D EN CHILE: 
ALCANCES METODOLÓGICOS
Valenzuela P1, Vignau A1, Olivares-Tirado P2, Muñoz A2, Kind P3, Zarate V3
1Consultor DATAVOZ / STATCOM, Santiago, Chile, 2Superintendencia de Salud, Santiago, 
Chile, 3University of York, York, UK
OBJECTIVOS: Obtener la valoración social de los estados de salud de EQ-5D en una 
muestra representativa de la población de Chile y determinar con ello, el índice social 
EQ-5D de la totalidad de estados de salud de EQ-5D (243). METODOLOGÍAS: Se 
entrevistaron a 2000 personas de 20 años y más, residentes de la Región Metropoli-
tana de Chile, a las que se les aplicó el cuestionario EQ-5D/VAS, recogiéndose además 
datos sobre variables sociodemográﬁcas relevantes. Luego, se evaluaron 42 estados de 
salud mediante los métodos VAS, ranking y equivalencia temporal (TTO). Los 42 
estados de salud utilizados corresponden a los mismos utilizados en el estudio Mea-
surement and Valuation of Health (MVH) del Reino Unido en 1993. RESULTADOS: 
Se obtuvo la valoración para los 42 estados de salud, con las diferentes metodologías 
señaladas. Las tasas de respuesta y niveles de consistencia fueron similares a los 
observados en estudios de países desarrollados. Se observó una diﬁcultad decre- 
ciente en la aplicación de las metodologías- VAS, ranking y TTO. Los resultados 
obtenidos mediante las tres técnicas se encuentran muy correlacionados entre si. 
CONCLUSIONES: La colaboración de la población encuestada y el compromiso del 
equipo de encuestadores, al ceñirse estrictamente a la metodología del estudio, res-
paldan la validez y conﬁabilidad de la información recopilada. Un trabajo de campo 
con énfasis en capacitación y control constante del proceso de recopilación de datos, 
permite reducir la tasa de no respuesta a niveles de países desarrollados. La aplicación 
secuencial de las tres metodologías permite obtener muy buenos resultados tanto en 
consistencia interna como en sus correlaciones.
MC2
SELF-PERCEPTION OF HEALTH IN LATIN AMERICA
Cabieses Valdes B1, Espinoza MA2, Zarate V3
1Universidad del Desarrollo, Santiago, RM, Chile, 2Pontiﬁcia Universidad Catolica de Chile, 
Santiago, RM, Chile, 3University of York, York, North Yorkshire, UK
OBJECTIVES: The capacity for planning and implementing public health policies 
requires knowledge and understanding of population’s health status. Information 
traditionally collected in population surveys is related to physical and biological mea-
surements; however, the self-perception of health has recently gained importance. This 
has occurred in light of the widespread phenomenon of an aging population and 
increased prevalence of chronic diseases and disabilities at international level. The 
study compared the self-perception of health-related quality of life (HrQoL) of six 
Latin American countries and its relationship with socio-demographic variables. 
METHODS: This study was based on secondary data collected for World Health 
Survey 2005. Participating countries in the region were Brazil, Paraguay, Uruguay, 
Mexico, Dominican Republic and Ecuador. A probabilistic sample was collected for 
each country, with sex and age national representation (n  67,734). The study 
outcome was HrQoL classiﬁed in 5 categories (Very Good, Good, Moderate, Bad, 
Very Bad). Analyses to estimate the existence of real differences on overall HrQoL 
between countries were performed through binary and ordinal logistic regressions. 
Results were adjusted by sex, age and educational level. RESULTS: The two countries 
A486 Rio Abstracts
that reported the best HrQoL in Latin America were Uruguay and Paraguay. Brazil 
in contrast, reported the worst HrQoL, as it had the highest proportion of people 
reporting a poor or very poor health-status. When comparing HrQoL between coun-
tries using logistic regression, signiﬁcant differences were found in the HrQOL for the 
6 nations. Results persisted after adjusting for mentioned socio-demographic variables. 
CONCLUSIONS: Our study supported the usefulness and importance of measuring 
HrQoL and showed that real differences in self-perceived health exist between Latin 
American countries. Future research should consider cultural aspects like language, 
ethnicity or macro indicators such as unemployment rates or gross domestic product 
per capita in a multilevel analysis, for further understanding of HrQoL in Latin 
America.
MC3
PREDICCIÓN DEL RIESGO CARDIOVASCULAR EN PACIENTES 
DIABÉTICOS TIPO 2 UTILIZANDO ÁRBOLES DE DECISIÓN:  
PRUEBA DE CONCEPTO
Quiroz E1, Santelices E2, Lahsen R2
1Universidad de Chile, Santiago, Chile, 2Clínica Las Condes, Santiago, Chile
OBJECTIVOS: Según la WHO (OMS), la principal causa de muerte a nivel mundial 
hasta el año 2005 han sido las enfermedades crónicas (65%) y se espera que su inci-
dencia aumente un 17% en los próximos diez años. El enfoque preventivo de estas 
enfermedades está cobrando máxima importancia, siendo particularmente relevante 
el poder determinar, de manera anticipada, las poblaciones de mayor riesgo. Se 
propone, utilizar nuevas herramientas de análisis de datos, buscando crear, mediante 
el modelamiento predictivo, conocimiento que sirva para generar acciones preventivas 
sobre los pacientes. METODOLOGÍAS: Se creó un repositorio con datos históricos 
de 397 pacientes del Centro de Diabetes de Clínica Las Condes (2000–2008). Se 
deﬁnieron 10 variables que, según la literatura, se consideran relevantes como factores 
de riesgo de padecer una enfermedad cardiovascular: sexo, edad, HbA1c, HDL, LDL, 
colesterol total, triglicéridos, presión sistólica, enfermedad coronaria anterior y 
tabaco. Utilizando técnicas data mining, especíﬁcamente técnicas de clasiﬁcación, se 
desarrolló un modelo basado en árboles de decisión, que permite predecir el nivel de 
riesgo que presentan los pacientes diabéticos tipo 2, de padecer una enfermedad car-
diovascular. RESULTADOS: Los resultados obtenidos presentan un nivel de certeza 
de 63%, que indica cuán bien podrá funcionar el predictor para clasiﬁcar futuros casos 
que desconoce. El riesgo alto de padecer un evento cardiovascular se logra predecir 
con un 85% de precisión y, el bajo, con un 62.5%. Los predictores más probables 
asociados al riesgo alto de padecer una enfermedad cardiovascular, son: enfermedad 
coronaria previa, LDL  100, HDL  55, HbA1c  7%, SBP  130 y que el paciente 
sea fumador. CONCLUSIONES: La predicción del riesgo es fundamental para el éxito 
de intervenciones proactivas, permitiendo deﬁnir distintos niveles de intervención, con 
el propósito de obtener mejores resultados clínicos y costo efectivos. La aplicación de 
esta metodología en poblaciones con riesgo desconocido, podría facilitar el desarrollo 
de programas de disease management.
MC4
COMPARISON OF DATA AVAILABILITY AND QUALITY FOR 
PHARMACOECONOMIC ANALYSIS IN BRAZIL VERSUS THE UNITED 
STATES AND EUROPEAN UNION: THE CASES OF DIABETES & 
HYPERTENSION
Araujo G1, Campbell J2, Parekh HH2, Fonseca MCM3, Goncalves L4, Incze A5, Vincze G5, 
Thompson D2
1Axia.Bio Consulting, São Paulo, Brazil, 2i3 Innovus, Medford, MA, USA, 3UNIFESP—Federal 
University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 4Novartis Biociências S/A, São Paulo, 
Brazil, 5Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To compare the availability and quality of data needed for pharmaco-
economic analysis in Brazil versus the US and EU, using diabetes and hypertension as 
case studies. METHODS: An extensive search was undertaken in Brazil for sources 
of epidemiologic, economic, outcomes, and life expectancy data needed for pharma-
coeonomic analysis in the areas of diabetes and hypertension. Potential sources 
included the published literature, holdings of national health authorities and govern-
ment statistical agencies, public and commercial insurers, pharmacy beneﬁt manage-
ment companies, and disease management ﬁrms. Identiﬁed data sources were 
evaluated according to ﬁve criteria: content; coverage; quality; reliability; and timeli-
ness. Sources identiﬁed in Brazil were then compared with corresponding sources 
commonly used in the US and EU. RESULTS: Many of the data elements needed for 
pharmacoeconomic analysis were identiﬁable in Brazil and comparable to US and EU 
sources on the ﬁve evaluation criteria. These included the costs of prescription drugs 
and health care services used in the treatment of diabetes and hypertension as well as 
age-speciﬁc mortality rates and life expectancies, which are freely available from the 
government data system (DATASUS) and available for purchase from selected com-
mercial database vendors. Notable gaps in requisite data in Brazil included large-
scale longitudinal epidemiologic studies analogous to the UK Prospective Diabetes 
Study (UKPDS) and the US Framingham Heart Study, needed to estimate longitudi-
nal risks of diabetes- or hypertension-related cardiovascular events. In addition, 
country-speciﬁc utility data of relevance to diabetes and hypertension were not 
found. CONCLUSIONS: Brazilian data sources are available and of sufﬁciently high 
quality to be used in pharmacoeconomic analyses in diabetes or hypertension. 
However, in the absence of Brazilian longitudinal epidemiologic data and disease-
speciﬁc utilities, scientiﬁcally rigorous analyses for the Brazilian setting likely would 
require local adaptation of models and data from other countries in North America 
or Europe.
PODIUM SESSION II: COST STUDIES II
CS5
GASTOS ELEVADOS COM MEDICAMENTOS DO PROGRAMA DE 
MEDICAMENTOS EXCEPCIONAIS DO MINISTÉRIO DA SAÚDE/BRASIL
Brandao CMR1, Acurcio FA1, Andrade IG1, Cherchiglia ML1, Silva GD2, Guerra Jr AA2, 
Almeida AM1, Queiroz OV1, SZuter DC1, Faleiros DR2, Jorge EA3
1Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 2Secretaria de 
Estado da Saúde de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 3Ministério da Saúde, 
Brazília, Distrito Federal, Brazil
OBJETIVOS: Analisar gastos elevados com medicamentos do Programa de Medica-
mentos Excepcionais do Ministério da Saúde. MÉTODOS: Trata-se de um estudo de 
gastos do Ministério da Saúde com medicamentos do Programa de Medicamentos 
Excepcionais. Os dados foram provenientes dos registros das Autorizações de Procedi-
mentos de Alta Complexidade, obtidos por pareamento probabilístico-determinístico, 
o qual gerou uma coorte histórica com 611,419 indivíduos com registros de gastos 
no período de 2000–2004. Foram analisadas as características dos usuários que apre-
sentaram gastos elevados no período de 2000–2004, que incluíram os gastos totais 
situados a partir do percentil 99, em uma distribuição de gastos feitos para cada 
indivíduo, ordenada em ordem crescente. Fez-se uma descrição segundo a distribuição 
etária, sexo, região de residência, medicamentos utilizado no início do tratamento e 
diagnóstico no início do tratamento, agrupados por capítulos da Classiﬁcação Inter-
nacional de Doenças (CID-10). RESULTADOS: Dentre os usuários, 6,114 indivíduos 
(1%) produziram os maiores gastos no período, num total de R$772 milhões (26.3% 
do total). Desses pacientes, 55.1% eram do sexo feminino, 76.5% tinham de 20–59 
anos (média de 36 anos) e 56.8% residiam na região sudeste. Os maiores gastos foram 
observados em maior frequência nos pacientes que iniciaram o tratamento utilizando 
imiglucerase e interferon (Beta 1a, 1b, alfa peguilado) e que tinham diagnóstico de 
doenças do sistema nervoso e de doenças endócrinas, nutricionais e metabólicas. 
CONCLUSÕES: Os medicamentos mais caros são responsáveis por altos gastos do 
Ministério da Saúde e destinados a uma pequena parcela da população, predominante-
mente adultos, residentes na região sudeste e portadores de doenças crônicas. Deve-se 
salientar a importância de sistemas universais de saúde, que possibilitam o acesso ao 
tratamento dessas doenças, mas que deve ser fundamentado no uso racional de medi-
camentos. A maioria da população não teria como arcar com estes gastos, tendo em 
vista a renda per capita nacional.
CS6
THE INTRODUCTION OF PRE-ENDOSCOPY (EGD) HIGH-DOSE 
INTRAVENOUS PROTON PUMP INHIBITION (HDIVPPI) IN  
THE MANAGEMENT OF PATIENTS WITH ACUTE UPPER 
GASTROINTESTINAL BLEEDING (UGIB)—A BUDGET IMPACT 
ANALYSIS
Barkun A1, Teich V2, Gralnek IM3, Bardou M4, Adam V5
1McGill University, Montreal, Quebec, Canada, 2MedInsight, Rio de Janeiro, Brazil, 3Rambam 
Health Care Campus, Haifa, Israel, 4University of Burgundy, Dijon, Bourgogne, France, 
5McGill University, Montreal, QC, Canada
OBJECTIVES: To quantify the budget impact of using HDIVPPI before EGD in 
ambulatory patients presenting with acute, overt UGIB in different clinical scenarios. 
METHODS: A decision tree compared pre-EGD HDIVPPI to none in a model that 
emulates contemporary standards of care. Patients were stratiﬁed by clinical likelihood 
of rebleeding (high/low), time to EGD, method of endoscopic hemostasis (epinephrine 
injection/other), and early discharge when clean-base ulcers are noted (frequent/rare). 
Probabilities and lengths of stay originated from the literature and bleeding registries. 
Hospital and additional pharmacological costs came from the Nationwide Inpatient 
Sample and Red Book (2008 $US). Expert consensus was sought when needed. 
Esomeprazole was the PPI in the base-case. One-way deterministic sensitivity analyses 
were performed on all variables across wide pre-set ranges. Model time horizon was 
30 days, adopting a third-party payer perspective. RESULTS: In the base-case, average 
costs were $9139 for the pre-EGD HDIVPPI strategy and $9029 for the arm without. 
This increment rose slightly amongst patients with a high clinical likelihood of rebleed-
ing ($117/pt) or when using only hemostatic methods other than epinephrine injection 
($128/pt). It dropped amongst patients undergoing epinephrine injection ($95/pt) or 
a late EGD ($37/pt). All mean costs were lowest, and this time favoring the HDIVPPI 
approach, when clean-base ulcer patients were discharged early ($8,263 for HDIVPPI 
versus $8,282 for none).In sensitivity analyses, variables with the greatest impact were 
the per diem cost of hospital stay complicated by rebleeding, and elapsed times 
to early or late EGD; overall per patient incremental costs varied from $16-$174. 
CONCLUSIONS: The introduction of HDIVPPI prior to EGD in a US managed care 
setting amongst acute UGIB patients in most scenarios raise modestly mean patient 
costs. This approach, however, becomes cheaper than no PPI administration pre-EGD 
when selected patients bleeding from clean-base ulcers are discharged home from the 
emergency room.
CS7
COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING 
ROSUVASTATIN INTO THE BRAZILIAN NATIONAL DRUG FORMULARY
Godoy MR1, Bueno RLP2
1UFRGS—Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Su, Brazil, 
2UFF—Fluminense Federal University, São Paulo, Brazil
OBJECTIVES: To assess the cost-effectiveness of Rosuvastatin in the treatment of 
hypercholesterolemia under the Brazilian Public Health Care System (SUS) perspective. 
